Socioeconomic Costs of Chronic Kidney Disease: Evidence from Southwest Vietnam LC99-LC105
Trung Quang Vo,
Department of Pharmacy Administration, Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City,
Ho Chi Minh City-700000, Vietnam.
Introduction: Chronic Kidney Disease (CKD) has a high mortality in developing countries. This burden is increasing rapidly in Vietnam. The high cost of medication and haemodialysis are major barriers in the successful treatment of CKD.
Aim: To determine from a societal perspective the complete cost associated with CKD.
Materials and Methods: A cross-sectional study was conducted to estimate the total costs associated with the cost-of-illness, based on the prevalence of the disease at Kien Giang General Hospital. An electronic database provided information related to direct medical costs and biochemical parameters, whereas face-to-face interviews with CKD patients were conducted by questionnaire to collect demographic characteristics, direct nonmedical costs and indirect costs. The population was divided into three groups based on the stages of CKD including the CKD 1â€“3 group, CKD 4â€“5 pre-dialysis group and haemodialysis group.
Results: A total of 327 patients were enrolled in the study. Costs varied among three groups of CKD patients. The annual cost per patient in the CKD 1â€“3 group, CKD 4-5 pre-dialysis group and haemodialysis group were USD 2,826.3 (95%CI: 2,592.3â€“ 3,077.1), USD 3,320.3 (95%CI: 2,765.2â€“3,913.8) and USD 9,498.3 (95%CI: 9,152.5â€“9,881.4), respectively. Direct medical costs represented the greatest proportion of total costs. The annual cost per patient in the CKD 1â€“3 group was affected by many characteristics such as age, residence, BMI, education level, exercise and number of comorbidities. In contrast to the CKD 1â€“3 group, in the haemodialysis group most results were not significantly different in the yearly cost per patient according to demographic and clinical characteristics. Whereas, patients in the CKD 4â€“5 pre-dialysis group were impacted by factors such as age, residence, occupation and the number of comorbidities.
Conclusion: The annual cost per patient in CKD 1â€“3, CKD 4â€“5 pre-dialysis and haemodialysis groups were substantial. Patients on haemodialysis incurred the highest cost, about three times compared with the other two groups. The differences in demographic and clinical characteristics affected the annual cost per patient, especially in the CKD 1â€“3 group.